Stigmasterol attenuates nociplastic pain and fatigue-like symptoms in a reserpine-induced fibromyalgia model in mice
Inflammopharmacology · 2026-01 · 34 (1) · 509-523
DOI: 10.1007/s10787-025-02068-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, online erschienen am 08.12.2025. Verfasst von Ana Clara Perazzio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pain Neurobiology (LabNeuro), Federal University of Santa Maria, Santa Maria, RS, Brazil. Hauptthemen laut MEDLINE: Fibromyalgia, Nociplastic Pain, Reserpine, Stigmasterol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Fibromyalgia is a widespread painful condition prevalent in women. The main manifestations include spontaneous pain, mechanical and thermal allodynia, and comorbid symptoms such as fatigue and migraine, impacting the patients’ quality of life. Treatments for this disease have limited effectiveness and cause adverse effects, making it necessary to search for alternative therapies. Stigmasterol is a phytosterol with antinociceptive effects in clinically relevant experimental pain models. Therefore, we investigated stigmasterol’s effect on painful and fatigue-like symptoms in a reserpine-induced experimental fibromyalgia model in mice. Adult female C57BL/6 mice received reserpine subcutaneously (1 mg/kg) once a day for three consecutive days. Mice submitted to the fibromyalgia model developed plantar mechanical and cold allodynia, mechanical-induced affective-motivational behaviour, heat thermal hyperalgesia, loss of muscle strength, and periorbital mechanical allodynia. Stigmasterol (0.3, 1, and 3 mg/kg, single dose, orally) reduced plantar mechanical allodynia and mechanical-induced affective-motivational behaviour in a time- and dose-dependent manner. Stigmasterol (3 mg/kg, orally) also reduced cold allodynia, heat thermal hyperalgesia, periorbital mechanical allodynia, and loss of muscle strength caused by reserpine, without causing motor impairment. Pregabalin (30 mg/kg, orally), Food and Drug Administration-approved for fibromyalgia treatment, and sumatriptan (0.6 mg/kg, orally), an anti-migraine drug, were used as reference drugs and reduced the nociceptive behaviours caused by reserpine. Our findings demonstrate that stigmasterol attenuated nociplastic pain and fatigue-like symptoms in the reserpine-induced fibromyalgia model in mice, highlighting its potential as a promising therapeutic candidate for alleviating pain-related symptoms in fibromyalgia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pain Neurobiology (LabNeuro), Federal University of Santa Maria, Santa Maria, RS, Brazil.
- Graduate Program in Biological Sciences: Toxicological Biochemistry, Centre of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.
- Graduate Program in Biological Sciences: Biochemistry: Biochemistry, Institute of Basic Health Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul (RS), Brazil.
- Laboratory of Pain Neurobiology (LabNeuro), Federal University of Santa Maria, Santa Maria, RS, Brazil. saramarchesan@hotmail.com.
- Graduate Program in Biological Sciences: Toxicological Biochemistry, Centre of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil. saramarchesan@hotmail.com.
- Department of Biochemistry and Molecular Biology, Federal University of Santa Maria, Camobi, Santa Maria, 97105-900, RS, Brazil. saramarchesan@hotmail.com.
Förderung
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Perazzio, A. C., Lopes, J. P. V., Becker, G., Brum, E. S., & Oliveira, S. M. (2026). Stigmasterol attenuates nociplastic pain and fatigue-like symptoms in a reserpine-induced fibromyalgia model in mice. Inflammopharmacology, 34(1), 509-523. https://doi.org/10.1007/s10787-025-02068-3
Vancouver
Perazzio AC, Lopes JPV, Becker G, Brum ES, Oliveira SM. Stigmasterol attenuates nociplastic pain and fatigue-like symptoms in a reserpine-induced fibromyalgia model in mice. Inflammopharmacology. 2026;34(1):509-523. doi:10.1007/s10787-025-02068-3
BibTeX
@article{Perazzio2026,
author = {Perazzio, Ana Clara and Lopes, João Pedro V and Becker, Gabriela and Brum, Evelyne Silva and Oliveira, Sara Marchesan},
title = {Stigmasterol attenuates nociplastic pain and fatigue-like symptoms in a reserpine-induced fibromyalgia model in mice},
journal = {Inflammopharmacology},
year = {2026},
volume = {34},
number = {1},
pages = {509--523},
doi = {10.1007/s10787-025-02068-3}
}
EUVIMED